CITIUS ONCOLOGY, INC. — Investor Relations & Filings
Filings indexed
232
across all filing types
Latest filing
2026-06-01
Capital/Financing Update
Country
US
United States of America
Listing
US
CTOR
Citius Oncology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative targeted oncology therapies. Its lead product, LYMPHIR™ (denileukin diftitox-cxdl), is a targeted immune therapy approved by the U.S. Food and Drug Administration (FDA) in August 2024. LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The company's strategy involves expediting development pathways for treatments with reduced clinical risks and securing competitive advantages through intellectual property and regulatory exclusivity. Citius Oncology is a majority-owned subsidiary of Citius Pharmaceuticals, Inc.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 424B3 | 2026-06-01 | English | |
| CURRENT REPORT | 2026-06-01 | English | |
| REGISTRATION STATEMENT | 2026-05-29 | English | |
| PROSPECTUS SUPPLEMENT | 2026-05-22 | English | |
| CURRENT REPORT | 2026-05-15 | English | |
| QUARTERLY REPORT | 2026-05-15 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 47923744 | 424B3 | 2026-06-01 | English | ||
| 47923557 | CURRENT REPORT | 2026-06-01 | English | ||
| 47894173 | REGISTRATION STATEMENT | 2026-05-29 | English | ||
| 46858938 | PROSPECTUS SUPPLEMENT | 2026-05-22 | English | ||
| 46362239 | CURRENT REPORT | 2026-05-15 | English | ||
| 46362554 | QUARTERLY REPORT | 2026-05-15 | English | ||
| 41840563 | 8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer) | 2026-05-06 | English | ||
| 41497108 | 424B3 - CITIUS ONCOLOGY, INC. (0001851484) (Filer) | 2026-05-05 | English | ||
| 38179372 | 8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer) | 2026-04-28 | English | ||
| 32899802 | 8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer) | 2026-03-04 | English | ||
| 30316598 | SCHEDULE 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject) | 2026-02-18 | English | ||
| 32066545 | 10-Q Filing | 2026-02-13 | English | ||
| 32066479 | 8-K Filing | 2026-02-13 | English | ||
| 13408272 | PRELIMINARY INFORMATION STATEMENT | 2026-01-20 | English | ||
| 13408273 | Regulatory Filings 2026 | 2026-01-13 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
CITIUS ONCOLOGY, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33815/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33815 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33815 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33815 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33815}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CITIUS ONCOLOGY, INC. (id: 33815)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.